FDA approves agent to detect dangerous blood clots
This article was originally published in Clinica
Executive Summary
Diatide and Nycomed Amersham will begin jointly selling AcuTect, a new radiopharmaceutical to detect potentially fatal blood clots in the legs, in the US within two weeks. The agent, Diatide's first commercial product, was approved last week by the FDA.